Experts provided an update on juvenile dermatomyositis, discussing patient care, treatment options and the pathogenesis of disease.
Search results for: Janus kinase inhibitors
Manifestations of JIA: JIA-Associated Uveitis, sJIA & Lung Involvement in sJIA
JIA can manifest in a variety of ways. Experts discuss the implications of uveitis, systemic disease and lung involvement in sJIA.
How Immunosuppression May Affect COVID-19 Vaccine Response
Although we can expect to learn much more, preliminary data are now available on the potential safety and effectiveness of COVID-19 vaccines in rheumatology patients. The picture is likely to be nuanced, with not all types of immunoÂsuppressive treatments having identical impacts on vaccine response. Rheumatologists should use caution in interpreting early reports, while continuing…
Myositis Management: Clinical Trials Provide New Insights into Treatment Options
Advancements in the treatment of myositis are on their way, according to Hector Chenoy, PhD, FRCP, who outlined the latest clinical trials during the 2021 ACR State-of-the-Art Clinical Symposium.
Highlights, Pearls & News from ACR Convergence 2020
ACR CONVERGENCE 2020—In a year like no other, the 2020 virtual ACR Convergence was a meeting like no other. Nonetheless, the meeting introduced a healthy mix of clinical insights and take-home pearls, according to panelists in the meeting’s closing session, Bright Future: Discovery & Growth. In this session, panelists discussed some of the biggest news…
Cytokine Targets & Treatment Developments for Psoriatic Arthritis & Spondyloarthritis
ACR CONVERGENCE 2020—In recent years, a pathophysiological role for the interleukin (IL) 17/IL-23 axis in the development of psoriasis, enthesitis and inflammatory arthritis has been investigated in both rodent and human models. Clinical trials have demonstrated differential benefits for skin disease and joint disease in patients with psoriatic arthritis, axial spondyloarthritis (axSpA) and ankylosing spondylitis…
Tips for Balancing Medication Treatment & Risk in Elderly Patients
ACR CONVERGENCE 2020—With the inevitable decline in organ function that comes with age, and the likelihood that older patients (i.e., generally defined as older than 60 or 70, depending on the study) are on more than one medication due to multiple comorbidities, therapeutic drug treatment for older patients requires persistent vigilance and know-how, two experts…
Diagnostic Drill-Down: New Research Suggests Genetic Autoinflammatory Roots
Two experts discussed ongoing difficulties in diagnosing autoinflammatory disease, & promising new studies that point to possible genetic roots of autoinflammatory disease.
Interfering with Interferon: Experts Discuss IFN Signaling & IFN Inhibition Treatment Possibilities
NIH investigators describe key features and genetic causes of Mendelian interferonopathies, & treatment approaches that may indicate the efficacy of IFN inhibition.
A Year to Remember: Dr. Jinoos Yazdany Presents the 2020 Clinical Research Review
During ACR Convergence 2020, Jinoos Yazdany, MD, MPH, discussed innovative research into a potential treatment for lupus, medication tapering & more. These findings may influence the treatment of rheumatic disease in the future.
- « Previous Page
- 1
- …
- 3
- 4
- 5
- 6
- 7
- …
- 17
- Next Page »